EpiCom
18April2024

Best epidemiological abstracts at ECCO’24

Paul Henderson, EpiCom Member


Paul Henderson
© ECCO

A total of 116 abstracts with an epidemiology theme were accepted for presentation at the ECCO Congress in 2024. This represented an increase over the previous year, with total submissions in this category up by 20%. It is clear that ECCO Members and IBD researchers see epidemiology as a vital part of our understanding of the overall picture of IBD aetiology, management and outcomes. Here we highlight just a few of the top abstracts that caught our eye.

Posted in ECCO News, Committee News, Volume 19, Issue 1, EpiCom

18December2023

Empowering Patients: Insights from the 7th EpiCom Workshop

Sophie Restellini, EpiCom Member

Sophie Restellini
© ECCO

At the upcoming ECCO’24 Congress in Stockholm, the Epidemiological Committee (EpiCom) will hold its 7th Workshop on Wednesday, February 21.

In the dynamic landscape of healthcare, patients are now assuming a pivotal role beyond their traditional status as care recipients. They are emerging as active partners, capable of contributing invaluable insights to medical research. The theme of the 7th EpiCom Workshop will be "The patient as an Epidemiologist", and the workshop will aim to shed light on the empowering potential of patient involvement, underscoring the significance of utilising appropriate tools to assess clinically relevant outcomes. Moreover, it will emphasise the pivotal role of digital tools in enabling patients to directly contribute to the research process.

Posted in ECCO News, Committee News, Volume 18, Issue 4, EpiCom

26October2023

Preclinical IBD: the key to the future is (probably) behind us

Iago Rodríguez-Lago, EpiCom Member

Iago Rodríguez-Lago
© ECCO

Introduction

The incidence and prevalence of Inflammatory Bowel Disease (IBD) are progressively increasing worldwide, particularly in developing countries. Despite increasing awareness of IBD and improvements in biomarkers and diagnostic techniques, a significant diagnostic delay is still frequently observed. This is highly relevant as diagnostic delay prevents application of medical treatment during very early disease stages and the implementation of certain disease intervention strategies. Diagnostic delay is consequently still limiting our potential to alter the natural history of the disease, as has recently been shown by UK colleagues. In a systematic review and meta-analysis, it was demonstrated that individuals with Crohn’s Disease (CD) in the higher quartiles of diagnostic delay (median 24 months) were more likely to have stricturing or penetrating disease and were also more likely to undergo intestinal surgery, while in patients with Ulcerative Colitis (UC) such a delay was associated with increased probability of colectomy [1]. Hence, reducing diagnostic delay should be a priority if we are aiming to apply effective disease intervention strategies.

Posted in ECCO News, Committee News, EpiCom, Volume 18, Issue 3

15June2023

Introduction of new EpiCom Committee Members for 2023

Julien Kirchgesner, EpiCom Chair

Julien Kirchgesner
© ECCO

During the recent ECCO Congress in Copenhagen, EpiCom said goodbye to Valérie Pittet and Behrooz Z. Alizadeh while Kristine Allin and Iago Rodríguez-Lago were welcomed as new Committee Members. We thank Valérie and Behrooz for their dedication to ECCO and wish them huge success in their future academic activities.

Posted in ECCO News, Committee News, EpiCom, Volume 18, Issue 2

27April2023

Best epidemiological abstracts at ECCO’23

Ravi Misra, EpiCom Member


Ravi Misra
© ECCO

A total of 74 epidemiological abstracts and 18 digital oral presentations were presented at ECCO'23 in Copenhagen. Five abstracts of particular interest are discussed below.

A novel population-based UK study by Cooney and colleagues (OP 28) examined the association of IBD and various mental health disorders such as depression, anxiety and self-harm in children and adolescents. A large primary care database was used to identify cases. Each case was propensity matched with four controls. Relative risk of all outcomes up to 10 years in the IBD cohort versus controls was estimated using adjusted Cox proportional hazards models controlling for age, sex, socioeconomic status, ethnicity and other conditions. A total of 3898 young patients with incident IBD were matched to 15,571 controls. IBD patients were significantly more likely to develop PTSD [adjusted hazard ratio (aHR) 2.47, 95% CI 1.23–4.94], eating disorders (aHR 1.85, 95% CI 1.05–3.26), self-harm (aHR 1.49, 95% CI 1.00–2.21), sleep disturbance (aHR 1.40, 95% CI 1.15–1.71), depression (aHR 1.34, 95% CI 1.16–1.56) and anxiety disorder (aHR 1.25, 95% CI 1.06–1.48). These findings highlight the need to screen for these conditions in young patients.

Posted in ECCO News, Committee News, ECCO'23, EpiCom, Volume 18, Issue 1

27April2023

Best epidemiological abstracts at ECCO’23 (Copy)

Ravi Misra, EpiCom Member


Ravi Misra
© ECCO

A total of 74 epidemiological abstracts and 18 digital oral presentations were presented at ECCO'23 in Copenhagen. Five abstracts of particular interest are discussed below.

A novel population-based UK study by Cooney and colleagues (OP 28) examined the association of IBD and various mental health disorders such as depression, anxiety and self-harm in children and adolescents. A large primary care database was used to identify cases. Each case was propensity matched with four controls. Relative risk of all outcomes up to 10 years in the IBD cohort versus controls was estimated using adjusted Cox proportional hazards models controlling for age, sex, socioeconomic status, ethnicity and other conditions. A total of 3898 young patients with incident IBD were matched to 15,571 controls. IBD patients were significantly more likely to develop PTSD [adjusted hazard ratio (aHR) 2.47, 95% CI 1.23–4.94], eating disorders (aHR 1.85, 95% CI 1.05–3.26), self-harm (aHR 1.49, 95% CI 1.00–2.21), sleep disturbance (aHR 1.40, 95% CI 1.15–1.71), depression (aHR 1.34, 95% CI 1.16–1.56) and anxiety disorder (aHR 1.25, 95% CI 1.06–1.48). These findings highlight the need to screen for these conditions in young patients.

Posted in ECCO News, Committee News, ECCO'23, EpiCom, Volume 18, Issue 1

13October2022

New EpiCom member

Valerie Pittet, EpiCom Chair


Valerie Pittet 
© ECCO

As you probably know ECCO Members have to step down and new members take their place - that means fresh ideas and various perspectives are heard, leading to renewed enthusiasm that will drive the EpiCom agenda for the future. The Epidemiological Committee  would like to welcome Ravi Misra as board member, while saying good bye to former Chair Naila Arebi.

Posted in ECCO News, Committee News, EpiCom, Volume 17, Issue 3

15June2022

Genetics of IBD: the most relevant Genetics abstracts at ECCO’22

Behrooz Z. Alizadeh, EpiCom Member


Behrooz Z. Alizadeh
© ECCO

A total of ten abstracts focusing on IBD genetics were accepted for presentation at the 17th Congress of ECCO. Four abstracts were presented in the scientific programme (OP) and two in digital oral presentation (DOP) sessions. The remaining four abstracts were presented as posters (eP). I describe here the most interesting findings from different domains of genetics in IBD.

Posted in ECCO News, Committee News, EpiCom, ECCO'22, Volume 17, Issue 2

15June2022

Epidemiology of IBD: the most relevant epidemiological abstracts at ECCO’22

Behrooz Z. Alizadeh, EpiCom Member


Behrooz Z. Alizadeh
© ECCO

A total of 72 abstracts focusing on IBD epidemiology were accepted for presentation at the 17th Congress of ECCO. Among the best abstracts, seven were presented in digital oral presentation (DOP) sessions. The remaining 65 abstracts were presented as posters. Below, I summarise the most interesting studies, covering various fields in the epidemiology of IBD.

Posted in ECCO News, Committee News, EpiCom, ECCO'22, Volume 17, Issue 2

28April2022

6th EpiCom Workshop: Overview of prognostic factors and outcomes in IBD

Ravi Misra, EpiCom Member

Ravi Misra
© Ravi Misra

The Epidemiological Committee (EpiCom) organised the 6th EpiCom Workshop at the ECCO’22 Virtual Congress. The delegates were welcomed by EpiCom chair, Naila Arebi.

The opening presentation was a tandem talk by Naila Arebi and Valérie Pittet on core outcomes relevant to prognostic factors. The two different types of prognostic study, natural history and clinical course, were described, with identification of their strengths and weaknesses. Emphasis was placed on the importance of these studies in paving the way for personalised medicine by identifying high-risk groups and tailoring treatment accordingly. However, a significant limitation is the heterogeneity of outcomes, which limits comparison. Indeed, over 200 different outcomes have been described for Crohn’s Disease (CD) alone.

Posted in ECCO News, Committee News, EpiCom, ECCO'22, Volume 17, Issue 1